Glaukos Co. (NYSE:GKOS) Director Gilbert H. Kliman Sells 10,000 Shares

Glaukos Co. (NYSE:GKOS) Director Gilbert H. Kliman sold 10,000 shares of Glaukos stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $150.28, for a total transaction of $1,502,800.00. Following the sale, the director now owns 32,336 shares in the company, valued at approximately $4,859,454.08. This trade represents a 23.62 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Glaukos Price Performance

Shares of Glaukos stock traded down $2.52 during midday trading on Monday, reaching $148.36. The company had a trading volume of 446,681 shares, compared to its average volume of 576,100. The stock has a fifty day simple moving average of $138.42 and a 200 day simple moving average of $128.46. Glaukos Co. has a 1-year low of $74.75 and a 1-year high of $151.92. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $8.18 billion, a price-to-earnings ratio of -49.13 and a beta of 1.03.

Glaukos (NYSE:GKOS) last released its earnings results on Monday, November 4th. The medical instruments supplier reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.20. The company had revenue of $96.70 million during the quarter, compared to the consensus estimate of $91.50 million. Glaukos had a negative return on equity of 18.99% and a negative net margin of 42.43%. The firm’s quarterly revenue was up 23.9% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.50) earnings per share. As a group, equities research analysts forecast that Glaukos Co. will post -1.89 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Values First Advisors Inc. acquired a new stake in shares of Glaukos during the 3rd quarter worth approximately $25,000. Harvest Fund Management Co. Ltd boosted its stake in Glaukos by 2,263.2% in the third quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier’s stock valued at $117,000 after acquiring an additional 860 shares during the last quarter. KBC Group NV grew its holdings in Glaukos by 16.2% during the 3rd quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier’s stock worth $188,000 after acquiring an additional 201 shares during the period. Brighton Jones LLC bought a new stake in shares of Glaukos during the 2nd quarter valued at $208,000. Finally, EWA LLC acquired a new position in shares of Glaukos in the 3rd quarter valued at $209,000. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have weighed in on GKOS. StockNews.com raised Glaukos from a “sell” rating to a “hold” rating in a report on Monday, October 21st. BTIG Research upped their price target on Glaukos from $140.00 to $149.00 and gave the company a “buy” rating in a research report on Tuesday, November 26th. Stephens raised shares of Glaukos to a “strong-buy” rating in a report on Monday, December 2nd. Truist Financial upped their price objective on shares of Glaukos from $152.00 to $185.00 and gave the stock a “buy” rating in a research note on Wednesday, December 18th. Finally, Citigroup upgraded shares of Glaukos from a “neutral” rating to a “buy” rating and lifted their target price for the company from $132.00 to $162.00 in a research note on Wednesday, December 11th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Glaukos currently has an average rating of “Moderate Buy” and an average target price of $145.92.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.